![]() |
市场调查报告书
商品编码
1597167
亚太地区临床参考实验室市场预测至 2031 年 - 区域分析 - 按服务提供者(医院、独立和诊所)和应用(检验医学、临床试验等)Asia Pacific Clinical Reference Laboratory Market Forecast to 2031 - Regional Analysis - by Service Provider (Hospital-Based, Standalone, and Clinic-Based) and Application (Laboratory Medicine, Clinical Trials, and Others) |
2023年亚太临床参考实验室市值为98.1413亿美元,预计2031年将达到165.1017亿美元;预计2023年至2031年复合年增长率为6.7%。
与参考实验室的策略性倡议推动亚太临床参考实验室市场
实验室服务提供者的策略性倡议,例如收购、联盟和与参考实验室的扩张,是获得更好的患者护理和成本效率的最具成本效益的方法之一。 2024 年,泰国领先的体外诊断 (“IVD”) 产品供应商 Hausen-Bernstein Co. Ltd 被印度和东南亚着名的市场准入和分销企业 Everlife Holdings Pte Ltd 收购。 2024 年,总部位于印度的下一代药物选择和疾病分层诊断公司 CORE Diagnostics 宣布计划在 50 个新城市扩大业务。 2023 年,Suburban Diagnostics 在孟买维迪亚维哈尔开设了其最大的「参考」实验室。这个超现代化的实验室将利用最先进的测试和製程自动化技术,提供全面的测试选单,以实现准确、快速的诊断。 2023 年,印度海得拉巴的临床参考实验室 TRUSTlab Diagnostics 与古尔冈的 NKV Path Labs 合作,将其诊断服务扩展到该国服务不足的地区。因此,越来越多的收购和与参考实验室的联盟预计将为市场成长提供重大机会。
亚太地区临床参考实验室市场概况
近几十年来,包括COVID-19和猴痘在内的多种传染病的出现,对人类健康构成了新的风险。中国的流行病学发生了快速变化,传染病控制取得了显着进展。在处理传染病问题时,尽快发现和定位疫情、识别病原体并确保妥善处置以最大程度地减少升级并预防和管理传染病至关重要。在医院或参考实验室进行各种测试来检测病原体。根据省级行政区统计,2014年至2021年,共记录疟疾病例5770例,99.05%的疟疾样本送交省级疟疾诊断参考实验室。省级疟疾诊断参考实验室在确保医疗机构疟原虫诊断的准确性和可靠性方面发挥了关键作用。上述因素正在推动该国的临床参考实验室市场。
亚太地区临床参考实验室市场收入及 2031 年预测(百万美元)
亚太地区临床参考实验室市场细分
亚太地区临床参考实验室市场按服务提供者、应用程式和国家/地区进行分类。
根据服务提供者,亚太地区临床参考实验室市场分为医院型、独立型和诊所型。 2023 年,医院细分市场占据最大市场份额。
从应用来看,亚太临床参考实验室市场分为检验医学、临床试验等。 2023 年,检验医学领域占据最大的市场份额。
依国家/地区划分,亚太地区临床参考实验室市场分为中国、日本、印度、澳洲、韩国和亚太地区其他地区。 2023年,中国在亚太临床参考实验室市场份额中占据主导地位。
Sonic Healthcare Ltd、Laboratory Corp of America Holdings、Quest Diagnostics Inc 和 Myraid Genetics Inc 是亚太临床参考实验室市场上的一些领先公司。
The Asia Pacific clinical reference laboratory market was valued at US$ 9,814.13 million in 2023 and is expected to reach US$ 16,510.17 million by 2031; it is estimated to register a CAGR of 6.7% from 2023 to 2031.
Strategic Initiatives with Reference Laboratories Boost Asia Pacific Clinical Reference Laboratory Market
Strategic initiatives by the laboratory service providers such as acquisition, alliance, and expansion with reference labs are among the most cost-effective ways to obtain the benefits of better patient care and cost efficiency. In 2024, Hausen-Bernstein Co. Ltd., the leading supplier of in-vitro diagnostic ("IVD") products in Thailand, was acquired by Everlife Holdings Pte Ltd, a prominent market access and distribution business in India and Southeast Asia. In 2024, CORE Diagnostics, a next-generation diagnostics for medication selection and disease stratification based in India, announced its plans to expand operations in 50 new cities. In 2023, Suburban Diagnostics opened its largest 'reference' laboratory in Vidya Vihar, Mumbai. This ultramodern laboratory will utilize state-of-the-art testing and process automation technologies to provide a comprehensive test menu for accurate and quick diagnosis. In 2023, TRUSTlab Diagnostics, a clinical reference laboratory in Hyderabad, India, partnered with NKV Path Labs in Gurugram to expand its diagnostic services to underserved areas of the nation. Thus, the increasing number of acquisitions and alliances with reference laboratories is expected to offer significant opportunities for market growth.
Asia Pacific Clinical Reference Laboratory Market Overview
In recent decades, the emergence of several infectious illnesses, including COVID-19 and monkeypox, has posed a new risk to human health. China has experienced a rapid epidemiological change, with notable advances in infectious disease control. When dealing with infectious disease concerns, it is critical to detect and locate the outbreak as soon as possible, identify the pathogen, and ensure proper disposal to minimize escalation and prevent and manage infectious diseases. Various tests are done in hospitals or reference laboratories to detect the pathogen. According to the provincial-level administrative divisions (PLADs), 5,770 malaria cases were recorded between 2014 and 2021, with 99.05% samples of malaria submitted to provincial malaria diagnosis reference laboratories. Provincial malaria diagnosis reference laboratories have played a critical role in guaranteeing the accuracy and reliability of Plasmodium diagnosis in healthcare facilities. The abovementioned factors are driving the clinical reference laboratory market in the country.
Asia Pacific Clinical Reference Laboratory Market Revenue and Forecast to 2031 (US$ Million)
Asia Pacific Clinical Reference Laboratory Market Segmentation
The Asia Pacific clinical reference laboratory market is categorized into service provider, application, and country.
Based on service provider, the Asia Pacific clinical reference laboratory market is segmented into hospital-based, standalone, and clinic-based. The hospital-based segment held the largest market share in 2023.
In terms of application, the Asia Pacific clinical reference laboratory market is categorized into laboratory medicine, clinical trials, and others. The laboratory medicine segment held the largest market share in 2023.
By country, the Asia Pacific clinical reference laboratory market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific clinical reference laboratory market share in 2023.
Sonic Healthcare Ltd, Laboratory Corp of America Holdings, Quest Diagnostics Inc, and Myraid Genetics Inc are some of the leading companies operating in the Asia Pacific clinical reference laboratory market.